Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Gatiflo 0.3% Ophthalmic Solution Recommended for Approval
April 26, 2004
- Application Review, Safety Measures Are PMDA's Main Roles: Director Miyajima
April 26, 2004
- REGULATORY NEWS IN BRIEF
April 26, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 26, 2004
- Selection of Antibacterials Taking Resistant Strains into Account Recommended: JAID Meeting
April 26, 2004
- Use of Inhalant Steroids in Asthma Treatment Delayed in Japan: JRS Meeting
April 26, 2004
- Most Specialists Not Satisfied with Drugs for Autoimmune Diseases
April 26, 2004
- Specialists Question Therapeutic GL on Gastric Ulcers
April 26, 2004
- Keizai Doyukai Presents Recommendation, "Toward the Advanced Healthcare Nation, Nippon"
April 26, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
April 26, 2004
- BULLETIN
April 19, 2004
- Website News
April 19, 2004
- PMDA to Expedite NDA Review Process, Strengthen Safety Measures
April 19, 2004
- REGULATORY NEWS IN BRIEF
April 19, 2004
- Switching from Dependent to Independent Management at Nat'l Hospitals: Dr Yazaki
April 19, 2004
- 124th Annual Meeting of the Pharmaceutical Society of Japan
April 19, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
April 19, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
April 19, 2004
- 1st 3Qtrs Business Results
April 19, 2004
- DIAGNOSTIC NEWS IN BRIEF
April 19, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…